Results 141 to 150 of about 182,433 (270)

Cytoreductive therapy reduces JAK2V617F+ blood velocity and adhesion to activated endothelium

British Journal of Haematology, EarlyView.
Angelica DaSilva, Taimur Ul Islam, Swati Menon, Julia Nguyen, Paul Krenik, Conglin Ruan, Xianghua Luo, David K. Wood, Joan D. Beckman   +8 more
wiley   +1 more source

Extensive Cerebral Venous Sinus Thrombosis With Obstructive Hydrocephalus in a Young Female With Underlying Essential Thrombocythemia: A Case Report

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT Persistent symptoms suggestive of idiopathic intracranial hypertension despite standard therapy should prompt urgent neuroimaging to exclude cerebral venous sinus thrombosis. When CVST is confirmed without an obvious provoking factor, evaluation for underlying myeloproliferative neoplasms, including JAK2‐positive essential thrombocythemia, is ...
Sarah Nafea, Tasmia Farooq, Md Abu Taher, Andrea Barros, Kyaw Naing Soe, Fawad Ali, Koshy Thomas   +6 more
wiley   +1 more source

Forest plot showing the achievement of SVR in CHC patients with genotype 1b treated with pegylated interferon α-2 plus ribavirin or pegylated interferon α-2 plus ribavirin plus a direct-acting antiviral.

, 2014
Forest plot showing the achievement of SVR in CHC patients with genotype 1b treated with pegylated interferon α-2 plus ribavirin or pegylated interferon α-2 plus ribavirin plus a direct-acting antiviral.
Caterina Sagnelli (430094), Evangelista Sagnelli (430095), Nicola Coppola (430089), Italo F. Angelillo (300520), Mariantonietta Pisaturo (430090)   +4 more
core   +1 more source

Lower Viral Response to Pegylated Interferon Alpha 2a Treatment of Chronic Hepatitis B in Roma People in Eastern Slovakia

Gastroenterology Research and Practice, 2016
Aim. To evaluate the compliance and virological response to pegylated interferon alpha 2a treatment of chronic hepatitis B in Roma population compared to majority Caucasian population in Slovakia. Methods. Retrospective evaluation of a cohort of all Roma
Sylvia Drazilova, Martin Janicko, Pavol Kristian, Ivan Schreter, Branislav Kucinsky, Marek Kozlej, Ivana Hockickova, Peter Jarcuska   +7 more
doaj   +1 more source

An Overlap of Erdheim–Chester Disease and Rosai–Dorfman Disease With Isolated Bone Lesions Presenting a Diagnostic Challenge: A Case Report

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT Some of the rarest diseases with cell accumulation in different organs are histiocytoses. Since these diagnoses are uncommon, other differential diagnoses must be excluded. We report a case of a 42‐year‐old man with episodes of knee pain and fever.
Maris Tulk, Reet Kuuse, Maksim Zagura, Hazem M. M. Ali, Liis Vahesaar   +4 more
wiley   +1 more source

Nemolizumab for Pruritus Control in Cutaneous T‐Cell Lymphoma: A Case Series

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Yenny Angela, Ralf Gutzmer, Rudolf Stadler   +2 more
wiley   +1 more source

Spontaneous Bilateral Vesical Artery Pseudoaneurysms Presenting With Massive Recurrent Hematuria and Obstructive Acute Kidney Injury: A Case Report

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT Spontaneous development of vesical artery pseudoaneurysm (VA‐PA) as a cause of life‐threatening hematuria is very rare. Most of the existing reports are due to trauma or other types of pelvic surgeries/urological procedures. Incomplete hemostasis in these patients can lead to subsequent complications such as clot retention, severe blood loss ...
Dheeraj Kumar Alias Sailish, Amisha Kumari, Hadia Jamil, Sardar Ravi Singh, Muhammad Hassaan Javaid, Muddassir Khalid, Fred Segawa   +6 more
wiley   +1 more source

Pegylated Interferon Lambda for Covid-19

New England Journal of Medicine, 2023
Mingqiang, Wang, Lingling, Tang, Lingtong, Huang   +2 more
openaire   +4 more sources

MEK inhibition achieves robust and durable responses in Erdheim–Chester disease

HemaSphere, Volume 10, Issue 10, October 2026.
Abstract Erdheim–Chester disease (ECD) is a rare histiocytic neoplasm characterized by heterogeneous clinical manifestations and limited evidence to guide targeted therapy. While MEK inhibitors (MEKi) are increasingly used, data on their real‐world efficacy, durability, and safety remain incomplete.
Francesco Pegoraro, Félicien Triboulet, Matthias Papo, Francesco Peyronel, Anita Argentieri, Jerome Razanamahery, Ahmed Idbaih, Polyzois Makras, Ofer Shpilberg, Oshrat Hershkovitz‐Rokah, Michael Girschikofsky, Matthew Collin, Kristian Bowles, Satyen H. Gohil, Rodothea Amerikanou, Emmanuel Ledoult, Tanguy Le Scornet, Mathilde de Menthon, Etienne Riviere, Xavier Boulu, Henry Dupuy, Achille Aouba, Stanislas Faguer, Xavier Solanich, Elena Sieni, Stéphane Barete, Chiara Bellino, Alessandro Tomelleri, Corrado Campochiaro, Lorenzo Dagna, Zahir Amoura, Jean‐François Emile, Fleur Cohen‐Aubart, Augusto Vaglio, Julien Haroche   +34 more
wiley   +1 more source

Chronic hepatitis C virus genotype 6 infection: Response to pegylated interferon and ribavirin

, 2008
Background. To date, no study has evaluated pegylated interferon for the treatment of chronic infection with hepatitis C virus (HCV) genotype 6. We aimed to determine the efficacy of pegylated interferon plus ribavirin for treating infection with ...
Fung, J, Lai, CL, Hung, I, Wong, D, Cheng, C, Young, J, Yuen, MF   +6 more
core   +1 more source